bpc-157 safety evidence human trials If worked as well as the internet says it does… …we'd probably have high quality by now. Instead we have... Lots of rat studies. Lots of podcasts. Lots of The Hidden Risks of BPC‑157:

Pleasant Hills Middle School 1968 11

Neuroprotection and Nervous-System Injury: BPC-157 is evaluated in studies related to brain and spinal cord injuries, looking at how it may support healing and reduce damage to nerve cells

Novartis Pluvicto established radioligand therapy as a commercial reality (2022+): Lutetium-177 PSMA-617 (Pluvicto) for metastatic castration-resistant prostate cancer achieved rapid adoption post-2022 launch, validating the peptide receptor radionuclide therapy platform and creating a template for multiple follow-on radioligand therapy programmes

The low IGF-I levels is caused by nutritionally acquired hepatic GH resistance from intra-portal hypoinsulinemia ( Table 1